ClinicalTrials.gg
CompletedNCT04023396Updated May 6, 2026Results posted

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

A Phase 2 interventional study of ABX464 in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 120 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 239 studies in Colitis, Ulcerative with a site in France — 46 open to participants now, 79 under way, 27 of them phase 3. Colitis, Ulcerative · France.

Enrollment
80th of 184
217 · median 196
Started
2020
with 14 others
Phase 2
60 of 239
8 open now
Registered
131st of 239
by date
Lead sponsor
7 of 239
Abivax S.A.

Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 80th largest by enrollment of the 184 interventional ones that give a count, is one of 15 that started in 2020, is one of 60 in phase 2, and was the 131st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

46 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 239 studies in Colitis, Ulcerative with a site in France, or all of them as a file.
02

Study summary

A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.

Read the detailed description

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-103 clinical study (induction study) and who are willing to continue their treatment. All subjects will receive ABX464 given at 50mg o.d regardless of their previous treatment and dose received in the ABX464-103 study (i.e. ABX464 100mg, ABX464 50mg, ABX464 25mg or Placebo). The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation. Subjects will be treated with ABX464 for an overall period of 48 weeks. Subjects will be followed up on a monthly basis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • moderate to severe ulcerative colitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have completed the 16-week induction treatment period (ABX464-103);
  • Patients are able and willing to comply with study visits and procedures as per protocol;
  • Patients should understand, sign and date the written voluntary form prior to any protocol-specific procedures are performed;
  • Patients should be affiliated to a social security regimen (for French sites only);
  • Females and males receiving the study treatment (potentially in combination with ) and their partners must agree to use a highly effective method during the study and for 6 months (180 days) after end of study or early termination. Contraception should be in place at least 2 weeks prior to screening. Women must be surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy) or in the state (no menses for 12 months without an alternative medical cause) or if of must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the patient. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle. Female and male patients must not be planning pregnancy during the trial and for 6 months post completion of their participation in the trial. In addition, male patients should use condom during the trial and for 6 months (180 days) post completion of their participation in the study. Male patients must not donate sperm as long as contraception is required.

Criteria that should be met by patients at week 48 to be eligible for 48 additional weeks of study treatment.

  • Patients should be in clinical response. Clinical response is defined as: a reduction in Modified Mayo Score ≥ 2 points and ≥ 30 % from baseline (induction) with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.
  • Patients able and willing to continue the study treatment and who are compliant with study visits and procedures and who signed the update of the written voluntary informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients who had major protocol deviation(s) in the induction study;
  • Patients who permanently discontinued study the treatment in induction study (ABX464-103) because of an adverse event (AE) regardless of relatedness to product;
  • Patients who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study;
  • Patients with any other severe acute or chronic medical or psychiatric condition or laboratory or (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study;
  • Patients who are participating or plan to participate in other investigational studies (other than induction study) during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    ABX464 50mg

    All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.

    Drug: ABX464

Interventions

  • DrugABX464

    ABX464 All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.

    Also known as: Obefazimod

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)

    Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0, and an endoscopy sub-score ≤1 (excluding friability), and at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score ≤1

    Time frame: week 48

Secondary outcomes

  1. Proportion of Patients With Clinical Response at Weeks 48 and 96 Compared to Baseline of Induction Study

    Proportion of patients with clinical response at week 48 Clinical response is defined as: a reduction in Mayo Score ≥ 3 points and ≥ 30 % from baseline with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.

    Time frame: Weeks 48 and 96

  2. Endoscopic Improvement at Weeks 48 and 96

    Proportion of patients with endoscopic improvement at week 48 among all patients. Proportion of patients with endoscopic improvement at week 96 among all patients. Endoscopic improvement is defined as a Mayo endoscopic sub score of ≤1 (excluding friability).

    Time frame: week 48 and week 96

  3. Endoscopic Remission at Weeks 48 and 96

    Proportion of patients with endoscopic remission at week 48 among all patients. Proportion of patients with endoscopic remission at week 96 among all patients. Endoscopic remission is defined as a Mayo endoscopic sub score of 0.

    Time frame: week 48 and week 96

  4. Sustained Endoscopic Changes at Week 48 and Week 96

    Proportion of patients with sustained endoscopic changes at week 48 and 96. Sustained endoscopic changes is defined as the number of patients with endoscopic changes at week 48 among patients who had endoscopic changes during the Induction study (at week 8 or week 16 of study ABX464-103).

    Time frame: weeks 48 and 96

  5. Change in Modified Mayo Score and in Partial Modified Mayo Score

    Change in Modified Mayo Score (MMS) at weeks 48 and 96 and in partial Modified Mayo Score (pMMS) MMS is a composite score of UC disease activity calculated as the sum of the following 3 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic evaluation, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. pMMS is a composite score of UC disease activity calculed as the sum of the following 2 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). The overall pMMS ranges from 0 to 6 where higher scores represent more severe disease.

    Time frame: From baseline to week 96

  6. Stool Frequency Subscore

    Participants recorded stool frequency using a paper subject diary on a daily basis. The stool frequency subscore ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools per day more than normal Score 2: 3 to 4 stools per day more than normal Score 3: 5 or more stools per day more than normal

    Time frame: From baseline to week 96

  7. Rectal Bleeding Score

    Participants recorded rectal bleeding in a paper subject diary on a daily basis. Rectal bleeding score is taken as the worst subscore of the three most recent scores within 7 days prior to the visit. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed A lower score represents an improvement in rectal bleeding.

    Time frame: From baseline to week 96

  8. C-Reactive Protein

    Change to baseline in C-Reactive Protein levels

    Time frame: baseline, week 24, week 48

  9. miRNA-124 Expression

    Change relative to baseline in miRNA-124 expression in rectal/sigmoidal biopsies at week 48 and in total blood at week 24 and week 48.

    Time frame: baseline, week 24 and week 48

  10. Incidence and Description of Adverse Events

    Number and rate of all adverse events, causally-related adverse events, all serious adverse events and causally-related serious adverse events classified by severity. Incidence of treatment-emergent serious adverse events, hospitalizations, total inpatient days. Incidence of adverse events leading to investigational product discontinuation. Number of clinically significant laboratory abnormalities.

    Time frame: From baseline to week 96

07

Results

Posted Apr 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneABX464 50mg
Started217
Completed164
Not completed53
Withdrew: Adverse event16
Withdrew: Death1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject14
Withdrew: Pregnancy4
Withdrew: Lack of efficacy3
Withdrew: Physician decision4
Withdrew: Other reason (e.g., ukraine crisis)10

Outcome measures

PrimaryProportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)

Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0, and an endoscopy sub-score ≤1 (excluding friability), and at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score ≤1

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)
ParticipantsABX464 50mg
Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)119
SecondaryProportion of Patients With Clinical Response at Weeks 48 and 96 Compared to Baseline of Induction Study

Proportion of patients with clinical response at week 48 Clinical response is defined as: a reduction in Mayo Score ≥ 3 points and ≥ 30 % from baseline with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.

Time frame:
Weeks 48 and 96
Reported as:
Count of participants · Participants
Proportion of Patients With Clinical Response at Weeks 48 and 96 Compared to Baseline of Induction Study
ParticipantsABX464 50mg
Week 48177
Week 96158
SecondaryEndoscopic Improvement at Weeks 48 and 96

Proportion of patients with endoscopic improvement at week 48 among all patients. Proportion of patients with endoscopic improvement at week 96 among all patients. Endoscopic improvement is defined as a Mayo endoscopic sub score of ≤1 (excluding friability).

Time frame:
week 48 and week 96
Reported as:
Count of participants · Participants
Endoscopic Improvement at Weeks 48 and 96
ParticipantsABX464 50mg
Week 48133
Week 96128
SecondaryEndoscopic Remission at Weeks 48 and 96

Proportion of patients with endoscopic remission at week 48 among all patients. Proportion of patients with endoscopic remission at week 96 among all patients. Endoscopic remission is defined as a Mayo endoscopic sub score of 0.

Time frame:
week 48 and week 96
Reported as:
Count of participants · Participants
Endoscopic Remission at Weeks 48 and 96
ParticipantsABX464 50mg
Week 4872
Week 9678
SecondarySustained Endoscopic Changes at Week 48 and Week 96

Proportion of patients with sustained endoscopic changes at week 48 and 96. Sustained endoscopic changes is defined as the number of patients with endoscopic changes at week 48 among patients who had endoscopic changes during the Induction study (at week 8 or week 16 of study ABX464-103).

Time frame:
weeks 48 and 96
Reported as:
Count of participants · Participants
Sustained Endoscopic Changes at Week 48 and Week 96
ParticipantsABX464 50mg
Sustained endoscopic improvement at Week 4853
Sustained endoscopic remission at Week 4813
Sustained endoscopic improvement at Week 9650
Sustained endoscopic remission at Week 9611
SecondaryChange in Modified Mayo Score and in Partial Modified Mayo Score

Change in Modified Mayo Score (MMS) at weeks 48 and 96 and in partial Modified Mayo Score (pMMS) MMS is a composite score of UC disease activity calculated as the sum of the following 3 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic evaluation, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. pMMS is a composite score of UC disease activity calculed as the sum of the following 2 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). The overall pMMS ranges from 0 to 6 where higher scores represent more severe disease.

Time frame:
From baseline to week 96
Reported as:
Mean · units on a scale
Change in Modified Mayo Score and in Partial Modified Mayo Score
units on a scaleABX464 50mg
MMS baseline ISB7.0 ± 1.07
MMS baseline BOLS4.0 ± 2.02
MMS Week 481.8 ± 1.47
MMS Week 961.5 ± 1.48
pMMS baseline ISB4.2 ± 1.01
pMMS baseline BOLS1.8 ± 1.31
pMMS Week 41.4 ± 1.17
pMMS Week 81.4 ± 1.24
pMMS Week 121.3 ± 1.22
pMMS Week 161.3 ± 1.2
pMMS Week 201.2 ± 1.14
pMMS Week 241.1 ± 1.06
pMMS Week 281.1 ± 1.09
pMMS Week 321.0 ± 1.00
pMMS Week 361.0 ± 0.98
pMMS Week 400.9 ± 0.94
pMMS Week 440.9 ± 0.98
pMMS Week 480.8 ± 0.88
pMMS Week 600.7 ± 0.80
pMMS Week 720.7 ± 0.84
pMMS Week 840.7 ± 0.93
pMMS Week 960.7 ± 0.79
SecondaryStool Frequency Subscore

Participants recorded stool frequency using a paper subject diary on a daily basis. The stool frequency subscore ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools per day more than normal Score 2: 3 to 4 stools per day more than normal Score 3: 5 or more stools per day more than normal

Time frame:
From baseline to week 96
Reported as:
Mean · score on a scale
Stool Frequency Subscore
score on a scaleABX464 50mg
Stool frequency - Baseline ISB2.6 ± 0.66
Stool frequency - Baseline BOLS1.4 ± 0.94
Stool frequency - Week 41.2 ± 0.89
Stool frequency - Week 81.2 ± 0.93
Stool frequency - Week 121.1 ± 0.93
Stool frequency - Week 161.1 ± 0.93
Stool frequency - Week 201.0 ± 0.92
Stool frequency - Week 241.0 ± 0.83
Stool frequency - Week 280.9 ± 0.87
Stool frequency - Week 320.9 ± 0.78
Stool frequency - Week 360.9 ± 0.82
Stool frequency - Week 400.8 ± 0.8
Stool frequency - Week 440.8 ± 0.8
Stool frequency - Week 480.7 ± 0.79
Stool frequency - Week 600.7 ± 0.73
Stool frequency - Week 720.7 ± 0.76
Stool frequency - Week 840.7 ± 0.77
Stool frequency - Week 960.6 ± 0.73
SecondaryRectal Bleeding Score

Participants recorded rectal bleeding in a paper subject diary on a daily basis. Rectal bleeding score is taken as the worst subscore of the three most recent scores within 7 days prior to the visit. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed A lower score represents an improvement in rectal bleeding.

Time frame:
From baseline to week 96
Reported as:
Mean · score on a scale
Rectal Bleeding Score
score on a scaleABX464 50mg
Rectal bleeding Score - Baseline ISB1.6 ± 0.72
Rectal bleeding Score - Baseline BOLS0.4 ± 0.66
Rectal bleeding Score - Week 40.2 ± 0.49
Rectal bleeding Score - Week 80.2 ± 0.56
Rectal bleeding Score - Week 120.2 ± 0.50
Rectal bleeding Score - Week 160.2 ± 0.51
Rectal bleeding Score - Week 200.2 ± 0.49
Rectal bleeding Score - Week 240.2 ± 0.46
Rectal bleeding Score - Week 280.1 ± 0.42
Rectal bleeding Score - Week 320.1 ± 0.39
Rectal bleeding Score - Week 360.1 ± 0.38
Rectal bleeding Score - Week 400.1 ± 0.37
Rectal bleeding Score - Week 440.1 ± 0.37
Rectal bleeding Score - Week 480.0 ± 0.23
Rectal bleeding Score - Week 600.0 ± 0.24
Rectal bleeding Score - Week 720.0 ± 0.24
Rectal bleeding Score - Week 840.1 ± 0.36
Rectal bleeding Score - Week 960.0 ± 0.22
SecondaryC-Reactive Protein

Change to baseline in C-Reactive Protein levels

Time frame:
baseline, week 24, week 48
Reported as:
Mean · mg/L
C-Reactive Protein
mg/LABX464 50mg
Baseline BOLS6.66 ± 12.17
Week 245.07 ± 10.43
Week 485.01 ± 11.31
SecondarymiRNA-124 Expression

Change relative to baseline in miRNA-124 expression in rectal/sigmoidal biopsies at week 48 and in total blood at week 24 and week 48.

Time frame:
baseline, week 24 and week 48
Reported as:
Mean · copy number/cell
miRNA-124 Expression
copy number/cellABX464 50mg
miR-124 - Rectal - Baseline0.00065 ± 0.00211
miR-124 - Rectal - Week 480.00255 ± 0.00252
miR-124 - Sigmoidal- Baseline0.00035 ± 0.00050
miR-124 - Sigmoidal- Week 480.00225 ± 0.00216
miR-124 - Blood- Baseline0.00000 ± 0.00000
miR-124 - Blood- Week 240.00011 ± 0.00015
miR-124 - Blood- Week 480.00013 ± 0.00026
SecondaryIncidence and Description of Adverse Events

Number and rate of all adverse events, causally-related adverse events, all serious adverse events and causally-related serious adverse events classified by severity. Incidence of treatment-emergent serious adverse events, hospitalizations, total inpatient days. Incidence of adverse events leading to investigational product discontinuation. Number of clinically significant laboratory abnormalities.

Time frame:
From baseline to week 96
Reported as:
Count of participants · Participants
Incidence and Description of Adverse Events
ParticipantsABX464 50mg
AEs149
TEAEs148
Related TEAEs54
SAEs18
TESAEs18
TEAEs leading to discontinuation of investigational product26
TEAEs leading to study discontinuation17

Adverse events

Collected over 96 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX464 50mg1/217 (0.5%)18/217 (8.3%)148/217 (68.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventABX464 50mg
ProctitisGastrointestinal disorders2/217
Left ventricular dysfunctionCardiac disorders1/217
PalpitationsCardiac disorders1/217
Colon dysplasiaGastrointestinal disorders1/217
VomitingGastrointestinal disorders1/217
ApendicitisInfections and infestations1/217
COVID-19Infections and infestations1/217
COVID-19 pneunomiaInfections and infestations1/217
UrosepsisInfections and infestations1/217
InjuryInjury, poisoning and procedural complications1/217
Most frequent other events
Showing 10 of 43
Most frequent other events
EventABX464 50mg
COVID-19Infections and infestations31/217
HeadacheNervous system disorders25/217
Colitis ulcerativeGastrointestinal disorders17/217
NasopharyngitisInfections and infestations15/217
Back painMusculoskeletal and connective tissue disorders12/217
ArthralgiaMusculoskeletal and connective tissue disorders11/217
Fecal calprotectin increasedInvestigations10/217
Blood cholesterol increasedInvestigations8/217
Abdominal painGastrointestinal disorders8/217
NauseaGastrointestinal disorders8/217

Baseline characteristics

Patients with moderate to severe UC who were previously enrolled in the ABX464 103 clinical study (induction study). All patients who completed the 16-week (± 4 days) induction treatment period (ABX464-103) were eligible for this maintenance study regardless of their clinical response. Enrolled patients in ABX464 104 clinical study were willing to continue treatment with ABX464 as long-term (maintenance) therapy of remission.

Age, Continuous
Age, Continuous(years)ABX464 50mg
Mean42.1 ± 13.77
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 50mg
Female84
Male133
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ABX464 50mg
Region of Enrollment
Region of Enrollment(participants)ABX464 50mg
Hungary17
Czechia12
Ukraine30
Spain1
Canada5
Austria7
Belgium8
Poland63
Italy17
Slovakia16
Slovenia3
France24
Serbia5
Germany9
08

Study locations

120 sites
  • Medizinische Universität Innsbruck
    Innsbruck, Austria
  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, Austria
  • Ordensklinikum Linz GmbH - Barmherzige Schwestern
    Linz, Austria
  • AKH - Medizinische Universität Wien
    Vienna, Austria
  • Gomel Regional Clinical Hospital
    Homyel, Belarus
  • Minsk city diagnostic center
    Minsk, Belarus
  • Regional Clinical Hospital
    Minsk, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, Belarus
  • Vitebsk regoinal clinical specialized center
    Vitebsk, Belarus
  • AZ Sint-Lucas
    Bruges, Belgium
  • C. H. U. St-Pierre
    Brussels, Belgium
  • University Hospitals Leuven - campus Gasthuisberg
    Leuven, 3000, Belgium
  • Brandon Medical Arts Clinic
    Brandon, Canada
  • South Edmonton Gastroenterology
    Edmonton, Canada
  • LHSC - Victoria Hospital
    London, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Canada
  • Mount Sinai Hospital
    Toronto, Canada
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, Czechia
  • Hepato-Gastroenterologie HK s.r.o.
    Hradec Králové, Czechia
  • MUDr. GREGAR s.r.o.
    Olomouc, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava-Kunčice, Czechia
  • Nemocnice Na Bulovce
    Prague, Czechia
  • Thomayerova nemocnice
    Prague, Czechia
  • Nemocnice Slany
    Slaný, Czechia
  • CHU Amiens - Hopital Sud
    Amiens, France
  • CHU Besançon - Hôpital Jean Minjoz
    Besançon, France
  • CHU Clermont Ferrand - Hôpital d'Estaing
    Clermont-Ferrand, France
  • Hôpital Beaujon
    Clichy, France
  • CHU de Grenoble - Hôpital Nord
    Grenoble, France
  • Centre Hospitalier Départemental Les Oudairies
    La Roche-sur-Yon, France
  • CHU Lille - Hôpital Claude Huriez
    Lille, France
  • Hôpital Nord - CHU Marseille
    Marseille, France
  • Hopital Saint Eloi
    Montpellier, France
  • CHU Nantes - Hôtel Dieu
    Nantes, France
  • CHU Nice - Hôpital de l'Archet 2
    Nice, France
  • CHU Reims - Hôpital Robert Debré
    Reims, France
  • CHU Rennes - Hôpital Pontchaillou
    Rennes, France
  • CHU de Rouen - Hôpital Charles Nicolle
    Rouen, France
  • CHU Saint Etienne - Hôpital Nord
    Saint-Etienne, France
  • CHU Strasbourg - Hôpital Hautepierre
    Strasbourg, France
  • Hopital Rangueil
    Toulouse, France
  • Hôpital de Brabois Adultes
    Vandœuvre-lès-Nancy, France
  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
    Berlin, Germany
  • Florence-Nightingale-Krankenhaus-Diakonie Kaiserswerth
    Düsseldorf, Germany
  • Klinikum der Johann Wolfgang Goethe-Universitaet
    Frankfurt, Germany
  • Studiengesellschaft BSF Unternehmergesellschaft haftungsbeschraenkt
    Halle, Germany
  • Universitaetsklinikum Halle (Saale)
    Halle, Germany
  • Medizinische Hochschule Hannover
    Hanover, Germany
  • Johanna-Etienne-Krankenhaus
    Neuss, Germany
  • Tumorzentrum Nordthueringen MVZ GmbH
    Nordhausen, Germany
  • Dr. Tasso Bieler
    Riesa, Germany
  • Universitaetsklinikum Ulm
    Ulm, Germany
  • DRC Gyogyszervizsgalo Kozpont Kft.
    Balatonfüred, Hungary
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, Hungary
  • Pannonia Maganorvosi Centrum
    Budapest, Hungary
  • Semmelweis Egyetem
    Budapest, Hungary
  • Debreceni Egyetem
    Debrecen, Hungary
  • Vasutegeszsegugyi Kft. - Debreceni Egeszsegugyi Kozpont
    Debrecen, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Győr, Hungary
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, Italy
  • Fondazione Poliambulanza Istituto Ospedaliero
    Brescia, Italy
  • Azienda Ospedaliero Universitaria Mater Domini
    Catanzaro, Italy
  • I.R.C.C.S Policlinico San Donato
    Milan, Italy
  • Ospedale Sacro Cuore Don Calabria
    Negrar, Italy
  • Azienda Ospedaliera di Padova
    Padova, Italy
  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
    Palermo, Italy
  • Azienda Ospedaliero Universitaria Pisana (Presidio di Cisanello)
    Pisa, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Italy
  • Istituto Clinico Humanitas
    Rozzano, Italy
  • Szpital Uniwersytecki nr 2 im.dr J. Biziela
    Bydgoszcz, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Centrum Medyczne Plejady
    Krakow, Poland
  • Santa Familia Centrum Badan, Profilaktyki i Leczenia
    Lodz, Poland
  • Wojskowy Szpital Kliniczny w Lublinie
    Lublin, Poland
  • Trialmed CRS
    Piotrkow Trybunalski, Poland
  • Centrum Medyczne Grunwald
    Poznan, Poland
  • KO-MED Centra Kliniczne Pulawy
    Puławy, Poland
  • Gabinet Lekarski Bartosz Korczowski
    Rzeszów, Poland
  • Centrum Zdrowia MDM
    Warsaw, Poland
  • Nzoz Vivamed
    Warsaw, Poland
  • Centrum Zdrowia Tuchow Sp. z o.o.
    Wierzchosławice, Poland
  • Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
    Wroclaw, Poland
  • Centrum Medyczne Oporow
    Wroclaw, Poland
  • LexMedica
    Wroclaw, Poland
  • Clinical Center " Dr Dragisa Misovic Dedinje"
    Belgrade, Serbia
  • Clinical Center Bezanijska Kosa
    Belgrade, Serbia
  • General Hospital Uzice
    Užice, Serbia
  • Alian s.r.o.
    Bardejov, Slovakia
  • Gastromedic, s.r.o.
    Nové Zámky, Slovakia
  • Gastro I, s.r.o.
    Prešov, Slovakia
  • Accout Center s.r.o.
    Šahy, Slovakia
  • Endomed, s.r.o.
    Vranov nad Topľou, Slovakia
  • General Hospital Celje
    Celje, Slovenia
  • University Medical Centre Maribor
    Maribor, Slovenia
  • General Hospital Murska Sobota
    Murska Sobota, Slovenia
  • Centro Médico Teknon
    Barcelona, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, Spain
  • Hospital Universitario de Gran Canaria Dr. Negrin
    Las Palmas de Gran Canaria, Spain
  • Hospital Quironsalud Malaga
    Málaga, Spain
  • CNE Cherkasy Regional Hospital of Cherkasy Regional Council
    Cherkasy, Ukraine

Showing the first 100 of 120 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vermeire S, Nitcheu J, Gineste P, Flatres A, Santo J, Scherrer D, Peyrin-Biroulet L, Dulai PS, Danese S, Dubinsky M, Tilg H, Siegmund B, Hisamatsu T, Shan K, Rabbat CJ, Sands BE. Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study. J Crohns Colitis. 2025 May 8;19(5):jjaf074. doi: 10.1093/ecco-jcc/jjaf074. PubMed 40417999 ↗
  • Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganic I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1024-1035. doi: 10.1016/S2468-1253(22)00233-3. Epub 2022 Sep 6. PubMed 36075249 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Feb 2023, 37 months.

Results were first posted in Apr 2025, 2 years 2 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 37 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2019
First posted
Jul 17, 2019
StartActual
Jan 13, 2020
Primary completionActual
Feb 23, 2023
CompletionActual
Feb 23, 2023
Results first posted
Apr 27, 2025
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04023396
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Jul 17, 2019
Start date
Jan 13, 2020
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023
Results posted
Apr 27, 2025
Last update
May 6, 2026

Study contacts

Severine VERMEIRE, MD
principal investigator · Universitaire Ziekenhuizen KU Leuven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion